Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance
Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.
How this was made
The 30-second read
Why it matters
The combination of record revenue, higher testing volume and pricing, and a guidance raise is likely to shift expectations for 2026 growth and cost structure, making the update actionable for positioning and risk management.
Market read
Traders can update models for Exagen’s 2026 revenue trajectory and profitability path based on the raised guidance and improved EBITDA/margins.
What to watch
The article highlights clinical evidence and AI tool strategy, but it does not quantify how much these will drive future test volumes or margins beyond the raised revenue range.
Background
Exagen sells autoimmune diagnostic testing (AVISE platform) and is working toward sustainable profitability.
Ticker impact
Exagen reported record Q2 2026 revenue of $19.9M (+16% YoY) and raised full-year guidance to $72M-$75M.
Near-term upside bias as traders reprice growth and profitability trajectory; follow-through depends on sustaining testing volume and pricing.
The article discloses multiple fresh, decision-relevant datapoints: record revenue, margin expansion, narrowed operating/net losses, and an explicit guidance increase.
Market effects
Supports the autoimmune diagnostics demand narrative and may improve sentiment toward profitable path-to-profitability in the diagnostics/testing space.
Limited direct regional spillover; primarily US small-cap healthcare sentiment.
Modest, as the catalyst is company-specific clinical and commercial performance.
Counterpoint
Guidance increase may reflect near-term execution and pricing rather than durable volume growth; adoption of AVISE CTD could still be uneven.
Key entities
- companyExagen
Reported record Q2 2026 revenue, improved profitability metrics, and raised full-year 2026 revenue guidance.
- productAVISE CTD
Autoimmune testing offering; volume and average selling price increased in Q2, supporting revenue growth.
- productAVISE Lupus
Clinical evidence publication is cited as potentially strengthening adoption.
